drugset / Trial / NCT00711269

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCT00711269

Phase 3 Completed 460 enrolled Sumitomo Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Timeline

Start
2008-06-27
Primary completion
2010-04-27
Completion
2010-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Lurasidone Small molecule 40 mg Oral
Subject Lurasidone Small molecule 80 mg Oral
Comparator Risperidone Other / unclassified Oral

Indications